Melanoma is widely known as a skin cancer, but it can originate inside the eye as well, often without any link to sun exposure. Eye-based forms — chiefly uveal and conjunctival melanoma — together account for roughly 2,000 new U.S. cases annually and present different risk patterns than cutaneous melanoma. Patients and doctors report that early stages frequently cause no pain or obvious symptoms, which makes routine eye exams important for timely detection and treatment. Experts warn that when undetected, ocular melanomas can invade deeper tissues and reduce treatment options.
- About 212,000 people in the U.S. are expected to be diagnosed with melanoma this year, and roughly 8,000 deaths occur annually from the disease.
- Ocular melanoma produces about 2,000 new U.S. cases each year; conjunctival melanoma is much rarer, near 130 U.S. cases annually.
- Skin melanoma diagnoses rose markedly: rates doubled from 1982 to 2011 and increased a further 31.5% between 2011 and 2019.
- Early ocular melanoma is often symptomless; later signs can include blurred vision, floaters, flashes, redness, irritation or a pupil shape change.
- Risk signals for eye melanoma differ from skin melanoma: light eye color and pre-existing eye conditions (for example, myopia) have been associated with higher risk, while the role of UV light is unclear.
- Treatment options include targeted plaque brachytherapy and localized laser therapy; many treated patients reach a state described as no evidence of disease (NED), though long-term monitoring is required.
Background
Melanoma arises when melanocytes — the pigment-producing cells in skin, eyes and hair — acquire mutations that drive uncontrolled growth. While cutaneous melanoma has a well-established link to ultraviolet radiation, ocular melanomas (which arise from the same cell type) do not have a clearly established association with sun exposure. Two primary ocular subtypes are uveal melanoma, which develops in the uvea (the eye’s middle layer), and conjunctival melanoma, which forms on the clear membrane covering the eye.
Epidemiological data show a long-term rise in melanoma diagnoses overall. The American Academy of Dermatology reports a doubling of melanoma incidence from 1982 to 2011 and a further 31.5% increase through 2019. Patterns vary by age and sex: for instance, women over 50 have experienced a steady annual rise in rates, while younger men have seen small declines. These broader trends have prompted clinicians to emphasize vigilance for both skin and eye signs of malignancy.
Main Event
Ocular melanomas are often silent at first. Patients may not notice symptoms until a tumor affects vision or causes visible changes at the eye surface. Conjunctival melanoma can produce redness, irritation, or a visible pigmented spot on the conjunctiva; uveal melanoma may manifest later as blurred vision, floaters, flashes, or an altered pupil shape as the tumor grows.
Case reports, such as that of Allison Dashow — diagnosed with ocular melanoma at 26 and treated four years ago — illustrate how surprising a diagnosis can be for young adults who do not associate eye changes with cancer. Dashow underwent surgery and short-term postoperative care, including a day of eye covering, and now participates in follow-up surveillance to monitor disease status. Clinicians stress that many ocular tumors are detected during routine eye exams before symptoms arise.
Diagnosis typically involves a comprehensive eye exam with specialized instruments that allow doctors to see small lesions inside and around the eye. If an abnormality is suspected, ophthalmologists use imaging and sometimes biopsy to characterize the lesion. Treatments aim to control local disease while preserving as much vision as possible; options include focal laser therapy and plaque brachytherapy, which delivers radiation directly to the tumor.
Analysis & Implications
Because ocular melanoma can be asymptomatic early on, reliance on symptoms alone is insufficient. Regular comprehensive eye exams — generally recommended every one to two years for adults, more frequently for those with risk factors — increase the chance of detecting small, treatable lesions. The fact that ocular forms do not mirror the UV-exposure pattern of cutaneous melanoma shifts prevention emphasis toward surveillance rather than solely sun-avoidance strategies.
The healthcare implications extend beyond diagnosis. Even when local control is achieved and a patient reaches NED status, ocular melanoma can have long-term surveillance needs because of the risk of late spread. Clinicians caution that the eye’s anatomical connection to the central nervous system and the complex vascular drainage of ocular tissues can influence patterns of progression and follow-up planning.
Public-health messaging should therefore balance skin-focused sun-safety advice with reminders that the eye can be a primary site for melanoma. Ophthalmic professionals, primary-care clinicians and dermatologists should coordinate care pathways so patients with suspicious eye findings receive expedited specialist assessment. For individuals, awareness of persistent visual changes — even if mild — should prompt prompt evaluation.
Comparison & Data
| Condition | Estimated U.S. Annual Cases |
|---|---|
| All melanoma (cutaneous & other) | ~212,000 diagnoses |
| Ocular melanoma (total) | ~2,000 diagnoses |
| Conjunctival melanoma | ~130 diagnoses |
| Melanoma deaths (U.S., annual) | ~8,000 deaths |
These figures show that ocular melanoma is a small fraction of overall melanoma diagnoses but carries outsized diagnostic challenges because it can be symptomless. The rarity of conjunctival melanoma underscores why many clinicians see it infrequently and rely on referral networks for optimal management. National trends in cutaneous melanoma incidence underscore a growing clinical workload for early detection across specialties.
Reactions & Quotes
Experts emphasize routine exams and careful inspection of the eye even when patients have no symptoms.
“Some eye cancers begin in or around the eye, while others represent spread from elsewhere in the body,”
Dr Jacqueline Bowen, President, American Optometric Association (optometrist)
Dr Bowen has stressed that specialized microscopes used in comprehensive exams can spot very small precancerous or cancerous lesions, which improves outcomes when found early.
“Uveal melanoma can be life-threatening because the retina connects directly to neural tissue, offering a pathway for spread if the tumor is missed,”
Dr Jacqueline Bowen (statement to media)
Patients who have experienced ocular melanoma often report surprise at the diagnosis and relief when lesions are found during routine screening rather than after symptom onset. These firsthand accounts reinforce clinical guidance about regular eye care.
Unconfirmed
- The precise role of ultraviolet radiation in the development of uveal and conjunctival melanoma remains unclear and is an area of ongoing study.
- Associations between specific eye colors or refractive errors and absolute risk are based on observational data and require further confirmation to define individual risk precisely.
Bottom Line
Melanoma is not limited to the skin: the eye is a recognized primary site for this cancer, and ocular cases require distinct clinical attention. Although ocular melanoma is rare relative to cutaneous disease, its tendency to be symptomless makes routine, comprehensive eye exams a key strategy for early detection and better outcomes.
For individuals, persistent visual changes — including new blur, floaters, unexplained redness, irritation, or any new pigmented spot on the eye surface — warrant prompt evaluation by an eye-care professional. Clinicians and public-health communicators should include the eye in melanoma awareness efforts so patients know to seek timely assessment.
Sources
- Daily Mail (news report)
- Melanoma Research Foundation (nonprofit research & patient advocacy)
- American Academy of Dermatology (professional association; epidemiological data)
- American Optometric Association (professional organization; clinical guidance)